Identify Hidden Opportunities of Familial Amyloid Cardiomyopathy Treatment Market with Key Players
Identify Hidden Opportunities of Familial Amyloid Cardiomyopathy Treatment Market with Key Players
Aggregation Identify Hidden Opportunities deposition of mutant wild-type transthyretin protein (TTR) heart results familial cardiomyopathy, eventually result heart failure. There several mutation TTR associated with familial cardiomyopathy, P24S, A45T, Glu51Gly, is substitution of for valine at position that occurs high African-Americans.
Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type. Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers amyloidosis heart such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis. Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period.
Transthyretin amyloid cardiomyopathy is a Transthyretin Amyloid Cardiomyopathy inherited slowly progressive disease, the most common (V122I) is seen predominantly Transthyretin Amyloidosis Treatment individuals African descent. There are three types amyloid cardiomyopathy: light-chain wild-type amyloidosis. All three forms amyloid cardiomyopathy are progressive fatal. For patients wild-type amyloidosis cardiomyopathy mutant amyloidosis cardiomyopathy.
Comments
Post a Comment